Ipamorelin
Grade BFrequently combined with CJC-1295 to mimic physiological GH pulsatility. Cleaner side-effect profile than GHRP-2/6.
Mechanism of Action
Pentapeptide ghrelin receptor (GHS-R1a) agonist that selectively stimulates pituitary GH release without significant effects on cortisol, prolactin, or appetite — unlike earlier secretagogues.
Typical Protocol
Dose
200–300 mcg
Frequency
1–3× daily
Duration
8–12 week cycles
Timing
Pre-bed and/or pre-training, fasted
Route
Subcutaneous injection
Half-life
~2 hours
Educational reference only — not medical advice.
Reported Benefits
- Selective GH pulse without cortisol elevation
- Improved recovery and sleep quality
- Minimal appetite stimulation
Side Effects
- Mild head rush
- Transient flushing
- Injection site reaction
Contraindications
- Active malignancy
- Pregnancy
- Uncontrolled diabetes
Known Interactions
GHRH analogues (CJC-1295)Synergistic GH release.
Somatostatin analoguesAntagonistic — avoid combination.
References
Comparison vs Alternatives
All Peptides →| Attribute | IpamorelinThis page | CJC-1295 | Semaglutide |
|---|---|---|---|
| Evidence | Grade B | Grade B | Grade A |
| Category | Growth Hormone | Growth Hormone | Metabolic |
| Best for | Selective GH secretagogue | Long-acting GHRH analogue | GLP-1 receptor agonist |
| Typical dose | 200–300 mcg | 1–2 mg (with DAC) | 0.25 → 2.4 mg |
| Frequency | 1–3× daily | Weekly | Weekly |
| Route | Subcutaneous injection | Subcutaneous injection | Subcutaneous weekly (oral form available) |
| Legal status | Research chemical. Not approved for human therapeutic use. | Research chemical. Not approved for human therapeutic use. | FDA-approved (Ozempic, Wegovy). Prescription required. |
| Action | Current page | View → | View → |